First, let’s get one thing straight. There is no “crisis.”
Now that Novartis, GlaxoSmithKline, AstraZeneca, Merck, and Sanofi have either scaled back or (in the case of GSK and AZ) abandoned any further Central Nervous System (CNS) R&D, the hand-wringing has begun, with distinguished professors like Dr. Steven E. Hyman writing alarmist editorials about the imperiled future of psych meds and articles in the media talking of a “crisis” in psych-med research. (The opening sentence of a recent editorial in Schizophrenia Bulletin was: “Psychopharmacology is in crisis.” The headline of Dr. Hyman’s piece is “Psychiatric Drug Development: Diagnosing a Crisis.”)
First, let’s get one thing straight. There is no “crisis.” A review of the new-drug pipeline shows that 137 active R&D programs have 417 ongoing development projects aimed at 19 psychiatric indications. Most of these programs are in Phase I or II trials. Psych-med R&D is more vigorous than ever.
The widely reported shutdown of CNS research programs at GSK and AZ (and the scale-backs at Pfizer and elsewhere) represent the continuation of a process begun long ago, to outsource riskier types of development to academia (which gets funding from the drug companies as well as government, via NIH and NMIH) and to smaller, less risk-averse drug companies (including startups) who eventually sell their projects back to the giant pharmas, once it looks like they’ve “got something.”
But the whole notion that a GSK or an AstraZeneca can convert R&D dollars into brand-new, never-tried-before, fundamentally innovative psych meds is ridiculous in the first place, because that’s not how development of new treatments works. You can only develop a targeted drug when you know the precise biochemical mechanism of action of the underlying disease. That’s not the case for depression, schizophrenia, or any of the other major psychiatric illnesses. As H. Christian Fibiger correctly points out in his Schizophrenia Bulletin piece:
The discovery of all three major classes of psychiatric drugs, antidepressants, antipsychotics, and anxiolytics, came about on the basis of serendipitous clinical observation. At the time of their discoveries, the mechanisms by which these molecules produce their effects were unknown, and it was only later that antipsychotics were shown to be D2 receptor antagonists, antidepressants monoamine reuptake inhibitors, and anxiolytics GABA receptor modulators. It is interesting and perhaps instructive to consider whether any of these classes of drugs could have been discovered by current drug discovery strategies. For example, what genetic or preclinical data exist that point to the D2 dopamine receptor as a likely target for antipsychotic activity? Presently there are no genetic data that suggest that this receptor is expressed or functions abnormally in psychotic disorders. And without the benefit of the prior clinical validation, it is difficult to see how preclinical data alone would point to the D2 receptor as an interesting potential target for the treatment of psychotic disorders. The same can be said for monoamine transporters with respect to depression where, like psychosis, there are no animal models based on disease pathophysiology and no compelling preclinical data pointing to these as potential targets for antidepressant drugs.
The best Big Pharma has been able to do over the years is craft me-too drugs once a serendipitous discovery has been made. But the serendipitous discoveries themselves (such as John Cade‘s discovery that injecting Guinea pigs with lithium urate made them placid) can’t be manufactured; they can’t be bought. They happen by accident.
The Latest Bing News on:
Psychiatric Drug Development
- Study finds biomarkers for psychiatric symptoms in patients with rare genetic condition 22qon April 26, 2024 at 10:18 am
A recent study led by UC Davis Health researchers provides new insights into the molecular changes linked to the rare genetic condition 22q11.2 deletion syndrome, or 22q. It found unique biomarkers ...
- Tennessee legislature adjourns. Here’s what lawmakers did and did not accomplish this yearon April 26, 2024 at 5:01 am
The 113th Tennessee General Assembly concluded on Thursday. Your guide to what lawmakers did and did not accomplish.
- Vancomycin May Be Losing Strength Against Common Deadly Infectionon April 26, 2024 at 4:46 am
Now, a new study suggests that the leading antibiotic used to fight it, vancomycin, may be losing potency against this killer. The second-line drug is fidaxomicin (Dificid). “If antimicrobial ...
- Mental health crisis centers and EmPATH units: offering care that busy ERs can’ton April 26, 2024 at 1:30 am
As national awareness of mental illness rises and innovative care models emerge, many advocates now see a rare opportunity to remake mental health crisis care for the better.
- Hold Rating on Bioxcel Therapeutics Amid Strategic and Clinical Trial Uncertaintieson April 25, 2024 at 11:11 pm
Analyst Graig Suvannavejh from Mizuho Securities maintained a Hold rating on Bioxcel Therapeutics (BTAI – Research Report) and keeping ...
- Tennis legend Billie Jean King says she’s using weight loss medication to help treat her binge eating disorder. Experts explain how it works.on April 25, 2024 at 1:34 pm
Dr. Jennifer Kraker, a psychiatrist with expertise in metabolic health and eating disorders, tells Yahoo Life that she’s found weight loss medications very effective for treating BED patients. As the ...
- Genentech parent Roche has cut 20% of risky drugs from pipeline and is adjusting its workforce to matchon April 24, 2024 at 8:08 am
Genentech parent Roche has shaved one of five projects from its drug portfolio since Q3 2023. Here’s what that means for the Bay Area biotech and its workforce.
- NC General Assembly’s “short session” convenes todayon April 24, 2024 at 3:00 am
The North Carolina General Assembly returns to Raleigh today for the 2024 “short session” — a session that figures to feature debates over familiar topics like public and higher education and funding ...
- Roche's pipeline rethink hits 20% of new molecules as cancer candidates join discard pileon April 24, 2024 at 1:27 am
The culls are part of a broader refocusing that has removed 20% of new molecules from the pipeline in recent quarters.
- Neurocrine scores surprise win with depression drugon April 23, 2024 at 8:50 am
Shares of the biotech rose about 5% after a medicine licensed from Takeda hit the main and key secondary goals of a mid-stage study focused on major depressive disorder.
The Latest Google Headlines on:
Psychiatric Drug Development
[google_news title=”” keyword=”Psychiatric Drug Development” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
[/vc_column_text]
The Latest Bing News on:
Drug research and development
- AI-Driven Drug Discovery by Pfizer and Austrian Institute Set to Transform Healthcareon April 26, 2024 at 5:38 am
Pfizer, the top pharmaceutical firm, and the Research Center for Molecular Medicine of the Austrian Academy of Sciences (CeMM) have developed an AI-driven drug discovery method The novel approach, ...
- Pfizer collab with Austrian research institute leads to new AI models for drug discoveryon April 26, 2024 at 3:29 am
A three-year collaboration between Pfizer and the Research Center for Molecular Medicine of the Austrian Academy of Sciences (CeMM), has resulted in a new AI-driven drug discovery method that could ...
- Internationally Renowned Botulinum Toxin Experts Join WizMedi Bio's New Botulinum Toxin Development Projecton April 25, 2024 at 10:51 pm
SEOUL, KOREA, April 26, 2024 (GLOBE NEWSWIRE) -- Dr. Eric A. Johnson and Professor Dirk Dressler, internationally renowned botulinum toxin experts, visited South Korea in March this year to join ...
- A shortcut for drug discovery: Novel method predicts on a large scale how small molecules interact with proteinson April 25, 2024 at 11:00 am
For most human proteins, there are no small molecules known to bind them chemically (so-called "ligands"). Ligands frequently represent important starting points for drug development but this ...
- AI Drug Developer Xaira Therapeutics Launches with $1B+on April 24, 2024 at 5:00 pm
Marc Tessier-Lavigne, PhD, Xaira Therapeutics founding CEO, and Bing presidential professor, head of laboratory at Stanford University AI-based drug developer Xaira Therapeutics has been launched with ...
- Alzheimer's drug development pipeline: Positive results, new insight on biomarkers position 2024 as 'learning year'on April 24, 2024 at 12:13 pm
The world of Alzheimer's treatments is at an inflection point as more potential drugs make their way out of clinical trials.
- AI is boosting drug discovery and development — and sparking questions about proprietary dataon April 23, 2024 at 1:51 pm
AI and Biotech panel at Life Science Innovation Northwest 2024. From left: Danielle Greenawalt, Lynda Stuart, Sean McClain, Jonathan Cohen and moderator ...
- Collaboration and Partnerships in Accelerating Cancer Drug Developmenton April 23, 2024 at 5:53 am
Lorna Rothery spoke to the Cancer Drug Development Forum’s Managing Director, Professor Jaap Verweij and Chairperson of the CDDF Board of Directors, Professor Ruth Plummer, about opportunities and cha ...
- Gastric Cancer Drug Pipeline Research 2024: Significant Advancements and Numerous Therapies with Over 200 in Developmenton April 23, 2024 at 4:29 am
The "Gastric Cancer - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering.The latest insights into the Gastric Cancer pipeline have revealed over 180 companies are ...
- Quotient Sciences new platform disrupts conventional drug development processeson April 23, 2024 at 3:12 am
At CPhI North America, Quotient Sciences is looking forward to reconnecting with its customers and giving them a preview of how we are looking to expand Translational Pharmaceutics further within the ...
The Latest Google Headlines on:
Drug research and development
[google_news title=”” keyword=”drug research and development” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]